| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11433044 | SCPHARMACEUTICALS | Pharmaceutical formulations for subcutaneous administration of furosemide |
Apr, 2034
(9 years from now) | |
| US9884039 | SCPHARMACEUTICALS | Pharmaceutical formulations for subcutaneous administration of furosemide |
Apr, 2034
(9 years from now) | |
| US10272064 | SCPHARMACEUTICALS | Pharmaceutical formulations for subcutaneous administration of furosemide |
Apr, 2034
(9 years from now) | |
Furoscix is owned by Scpharmaceuticals.
Furoscix contains Furosemide.
Furoscix has a total of 3 drug patents out of which 0 drug patents have expired.
Furoscix was authorised for market use on 07 October, 2022.
Furoscix is available in solution;subcutaneous dosage forms.
Furoscix can be used as use of a liquid formulation comprising furosemide to treat congestion due to fluid overload (edema) in adults with nyha class ii/iii chronic heart failure.
The generics of Furoscix are possible to be released after 03 April, 2034.
Drugs and Companies using FUROSEMIDE ingredient
Market Authorisation Date: 07 October, 2022
Treatment: Use of a liquid formulation comprising furosemide to treat congestion due to fluid overload (edema) in adults with nyha class ii/iii chronic heart failure
Dosage: SOLUTION;SUBCUTANEOUS
FUROSCIX family patents
